Rationale for the use of conjunctive anticoagulation during thrombolysis.
Jaffe
A S
AS
Cardiovascular Division, SUNY Health Science Center, Syracuse 13210, USA.
D001777:Blood Coagulation; D003328:Coronary Thrombosis / Q000097:blood / Q000188:drug therapy*; D010450:Endopeptidases / Q000502:physiology; D005338:Fibrin Fibrinogen Degradation Products / Q000502:physiology; D005341:Fibrinolysin / Q000502:physiology; D005342:Fibrinolysis; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D015912:Thrombolytic Therapy
D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D010450:Endopeptidases; D005341:Fibrinolysin